Exhibit 99.1

     TRANSGENOMIC'S WAVE(R) SYSTEM AND SURVEYOR(TM) NUCLEASE USED TO DETECT
          MUTATIONS ASSOCIATED WITH RESPONSE TO THERAPY IN LUNG CANCER

   HIGH-SENSITIVITY SCANNING FOR EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS IN
                               CLINICAL SPECIMENS

    OMAHA, Neb., Feb. 1 /PRNewswire-FirstCall/ -- Transgenomic Inc. (Nasdaq:
TBIO) announced today the publication of a study demonstrating the combined use
of its WAVE HS System and Surveyor Nuclease to enable detection of mutations in
the epidermal growth factor receptor (EGFR) gene in patients with non-small cell
lung cancer (NSCLC). The presence of EGFR mutations has previously been shown to
correlate with response to targeted therapeutics that inhibit EGFR. Importantly,
Transgenomic's technology provided superior sensitivity compared to direct DNA
sequencing, the most common approach currently employed to detect these
mutations.

    Dr. Pasi A. Janne and colleagues in the Lowe Center for Thoracic Oncology in
collaboration with the Translational Research Laboratory of the Center for
Clinical and Translational Research, Dana-Farber Cancer Institute, Boston, MA,
described this work in an article entitled "A Rapid and Sensitive Enzymatic
Method for Epidermal Growth Factor Receptor Mutation Screening," which was
published in the journal Clinical Cancer Research on February 1.

    Dr. Janne commented on the significance of this work: "The most common
method of detecting EGFR mutations involves direct sequencing of DNA isolated
from tumor cells that have been micro dissected from pathology specimens. This
often requires a relatively large biopsy specimen, effectively excluding a
significant number of patient specimens from analysis. Our approach enables
analysis of formalin-fixed paraffin-embedded tumor samples without micro or
gross dissection. This increases the number of useable specimens, which we
believe is critical for the continued development of targeted cancer
therapeutics and related molecular diagnostic tests."

    Collin D'Silva, Transgenomic's CEO, said, "The finding, first made in 2004,
that EGFR mutations exist in the majority of patients that respond to therapy
with drugs that inhibit EGFR, has been a catalyst for accelerated translational
and clinical research in this area. The excellent work by Dr. Janne and his
colleagues provides an example of the capability of the Dana-Farber Cancer
Institute's Translational Research Laboratory to utilize new tools and
technologies to address important clinically-relevant questions." D'Silva
continued, "We are pleased to see our technology deployed successfully in their
cutting-edge work, which we believe will ultimately have significant impact on
cancer patient care by making molecular diagnostic testing feasible for a
broader patient base."

    SURVEYOR technology is based on intellectual property licensed exclusively
from The Fox Chase Cancer Center, Philadelphia, Pa.

    About Transgenomic

    Transgenomic is a global company that provides versatile and innovative
products and services to the medical research and pharmaceutical markets.
Transgenomic's WAVE Systems are specifically designed for use in genetic
variation detection. They have broad applicability to genetic research and
molecular diagnostics. The emerging pursuit of personalized medicine is driving
the ongoing need to detect new, uncharacterized mutations and genetic
polymorphisms. The high analytical sensitivity of the WAVE System makes it a
uniquely enabling technology for the advancement of personalized medicine. To
date there have been over one thousand systems installed in over 30 countries
around the world. In addition to the sale of systems and consumables
Transgenomic provides services to pharmaceutical and biopharmaceutical companies
in preclinical and clinical development of targeted therapeutics. For more
information about the innovative genomics research tools developed and marketed
by Transgenomic, please visit the company's Web site at www.transgenomic.com.



    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements include, but
are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including the ability of the company's
technology to contribute toward the continued advancement of translational
research and the development of targeted cancer therapeutics. The known risks,
uncertainties and other factors affecting these forward-looking statements are
described from time to time in Transgenomic's reports to the Securities and
Exchange Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ materially from those
referred to in such statements. Accordingly, the company claims the protection
of the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press release is as of
the date of the release and Transgenomic does not undertake any duty to update
this information, including any forward-looking statements, unless required by
law.

SOURCE  Transgenomic Inc.
    -0-                             02/01/2006
    /CONTACT:  Robert J. Pogulis, Ph.D. of Transgenomic Inc., +1-845-782-9617,
or rpogulis@transgenomic.com/
    /Web site:  http://www.transgenomic.com /
    (TBIO)